The Global Exosome Market: Size, Forecast, Trials and Trends, 2026

1.1 Statement of this Report
1.2 Purpose of the Report
1.3 Executive Summary

2.1 Biogenesis of Exosomes
2.1.1 Uptake of Exosomes by Target Cell
2.2 The Structure of an Exosome
2.2.1 Molecular Contents of Exosomes
2.3 Types of Exosomes used in Exosome Industry
2.3.1 Natural Exosome Types
2.3.2 Engineered Exosomes
2.3.2.1 Engineered Exosomes by Type of Modification
2.4 Shift from cell therapy to Exosome Therapy
2.5 Expected Positive Developments in the Next Ten Years
2.6 Key Scientific Milestones in Medical Evolution of Exosomes
2.6.1 Key Scientific Milestones in Exosome Therapeutics
2.6.2 Key Scientific Milestones in Exosome Diagnostics
2.6.3 Key Scientific Milestones in Exosome-Based Aesthetics
2.6.4 Current Trends in Exosome Research
2.6.5 Current Trends in Exosome Patent Filings
2.6.6 Current Trends in Exosome-Based Clinical Trials

3.1 Diagnostics & Liquid Biopsies
3.2 Targeted Drug Delivery Systems
3.3 Regenerative Medicine & Aesthetics
3.4 Explosive Volume of Published Papers on Exosomes
3.4.1 Published Papers on Exosome Diagnostics
3.4.2 Papers in PubMed.gov on Exosome-Based Targeted Delivery Systems
3.4.3 Papers on Therapeutic Applications of Exosomes
3.4.3.1 Higher Output of Published Papers on Exosome Therapeutics
3.4.4 Utilization of Exosome Purification Methods in Research
3.4.5 Distribution of Exosome Publications by Disease Type
3.4.6 Exosome-Based PubMed Publications by Cancer Type
3.4.7 Exosome Research Publications by Geography
3.5 Cost of Laboratory Research & Publishing one Exosome Research Paper
3.6 Leading Exosome Research Institutions
3.7 Collaborations between Research Institutions and Commercial Entities
3.8 Recent Trends in PubMed Publications on Exosomes

4.1 Diagnostics & Liquid Biopsies
4.2 Drug Delivery Systems (DDS)
4.3 Therapeutics & Regenerative Medicine
4.4 The Steady Growth in number of Patent Filings
4.4.1 Percent Share of Exosome Patent Filings by Domains of Innovation
4.5 Exosome Patent Filing Jurisdictions
4.6 Applicants of Filed Exosome Patents
4.7 Exosome Patent Inventors
4.8 Owners of Filed Exosome Patents
4.9 Legal Status of Filed Patents
4.10 Notable Recently Granted Patents
4.11 Licensing of Exosome Patents
4.12 Number of Exosome Patents Assigned to Leading Companies
4.13 Key Current Trends in Exosome Patent Filings
4.13.1 Shift from Lipid Nanoparticles (LNPs) to Exosomes
4.13.2 Explosion in Engineered Exosomes
4.13.3 Precision Diagnostics and Liquid Biopsies
4.13.4 Plant-Derived Exosomes in Cosmeceuticals
4.13.5 Manufacturing and "Product-by-Process" Claims

5.1 Geographical Distribution of Exosome-Based Clinical Trials
5.2 Clinical Trials by Country
5.3 Clinical Trials by Phases
5.4 Funding for Clinical Trials
5.5 Exosome-Based Clinical Trials by Application
5.6 Major Diseases Addressed by Exosome-Based Clinical Trials
5.7 Clinical Trials Evaluating Exosomes as Cell-Free Therapeutics
5.8 Clinical Trials Evaluating Exosomes as Disease Diagnostics
5.9 Clinical Trials Evaluating Exosomes as Drug Delivery Vehicles

6.1 Venture Capital (VC) Funding
6.1.1 PranaX Corporation
6.1.2 RION Vet
6.1.3 EVerZom
6.1.4 Annie Aesthetic
6.1.5 Ciloa
6.1.6 ExoLab Italia
6.1.7 Esphera SynBio
6.1.8 Exogenus Therapeutics
6.1.9 EXO Biologics
6.1.10 INEXOPLAT
6.1.11 Mantra Bio
6.2 Partnership Deals in Exosome Sector, 2023-June 2026
6.2.1 ReNeuron Group Ltd. & Laverock Therapeutics
6.2.2 Esco Aster & Shine-On Biomedical
6.2.3 GENFIT & EVerZom
6.2.4 RION & Lonza
6.2.5 Taiwan Exosome Company (TEC) & Toyota Holdings
6.2.6 HeXun Biosciences & JY BioMed
6.2.7 Exogenus Therapeutics & Lonza
6.2.8 Capricor Therapeutics & NIAID
6.2.9 Cytiva & RoosterBio
6.2.10 SomesTech & ConvEyXo
6.2.11 Sartorius & RoosterBio
6.3 Acquisition Deals in Exosome Sector
6.3.1 Marijuana, Inc.
6.3.2 Mdxhealth
6.3.3 ARCHIMED
6.3.4 ExoCoBio
6.3.5 Evox Therapeutics
6.4 Licensing Deals in Exosome Space, 2023-June 2026
6.4.1 Evox Therapeutics & Rett Syndrome Research Trust (RSRT)
6.4.2 Esco Aster & Shine-On Biomedical
6.4.3 Exousia Pro & University of Central Florida (UCF)
6.4.4 PranaX Corporation & MD Anderson Cancer Center
6.4.5 Brexogen & BMI Korea
6.4.6 HeXun Biosciences & JY BioMed
6.4.7 Elevai Labs & Yuva Bioscience
6.4.8 TOPPAN Inc. & Dai Nippon Toryo Co
6.4.9 Coya Therapeutics & Carnegie Mellon University (CMU)
6.4.10 ResearchDx & INOVIQ Limited
6.4.11 ATUM & Codiak Biosciences
6.5 Fund-Raising Trends in Exosome Space
6.5.1 Key Funding Trends
6.5.2 Notable Capital Inflows

7.1 Ultracentrifugation (UC)
7.1.1 Differential Ultracentrifugation (DUC)
7.1.2 Density Gradient Ultracentrifugation (DGC)
7.2 Ultrafiltration (UF)
7.2.1 Tandem-Configured Ultrafiltration
7.2.2 Sequential Ultrafiltration
7.3 Size-Exclusion Chromatography (SEC)
7.4 Polymer Precipitation Method
7.5 Immunoaffinity Capture Method
7.6 Microfluidic Technique
7.6.1 Widely Utilized Exosome Isolation & Purification Kits

8.1 Key Technologies & Methods
8.1.1 Stirred-Tank Bioreactor (STR)
8.1.2 Vertical-Heel Bioreactors (VWBRs)
8.1.2.1 PBS Biotech Vertical-Wheel® Bioreactors
8.1.2.2 Eppendorf DASbox® and BioBLU® Platforms
8.1.3 Hollow-Fiber Bioreactors (HFBs)
8.1.3.1 Quantum Flex Cell Expansion System (Terumo BCT)
8.1.3.2 FiberCell Systems’ HFBR
8.1.3.3 CelliGen BLU or FiberCell Systems’ Cartridges (Cell Culture Company)
8.1.3.4 Xcellerex or WAVE Bioreactors (Cytiva)
8.2 Exosome-Depleted Media
8.2.1 Gibco Exosome-Depleted FBS (Thermo Fisher)
8.2.2 Exo-FBS (System Biosciences - SBI)
8.2.3 Exosome-Depleted Fetal Bovine Serum (Biowest)
8.3 Cell Engineering
8.3.1 Cargo Loading
8.3.1.2 Stable Transfection/Viral Transduction
8.3.2 Surface Modification
8.3.2.1 Genetic Engineering
8.3.2.2 Metabolic Labeling
8.3.3 Yield Enhancement
8.3.3.1 Key Strategies for Upstream Yield Enhancement
8.4 AIoT-Based Monitoring
8.5 Microfluidics
8.5.1 The Upstream Advantage of Microfluidics

9.1 Harvest Clarification
9.2 Concentration & Purification
9.3 Post-Isolation Modifications
9.3.1 Surface Functionalization
9.3.2 Membrane Permeabilization and Loading
9.3.3 Membrane Fusion
9.4 Formulation
9.5 Storage
9.5.1 Cryopreservation (-80°C)
9.5.2 Lyophilization (Freeze-Drying)

10.1 ExoShell Platform
10.1.1 ExoShell Technology
10.1.2 Typical Applications
10.2 ExoDE & ExoEDIT Platforms
10.2.1 ExoDE & ExoEDIT Technologies
10.2.2 Primary Therapeutic Focus
10.3 StealthX platform
10.3.1 StealthX Technology
10.3.2 Primary Applications
10.4 EXPLOR and Pure-Exo Platforms
10.4.1 Technologies
10.4.2 Therapeutic Focus
10.5 DeliverEX® Platform
10.5.1 Technology
10.5.2 Core Therapeutic Programs
10.6 engEx™ Platform
10.6.1 Technology
10.6.2 Key Clinical Applications
10.7 Exopeptidase™ Platform
10.7.1 Technology
10.7.2 Therapeutic Focus

11.1 Endogenous Loading (Cellular Modification)
11.1.1 Endogenous Exosome Loading Technologies
11.2 Exogenous Loading (Direct Modification)
11.2.1 Exogenous Loading Technologies
11.3 Surface Engineering (Targeting)
11.3.1 Molecules Anchored to Exosomes for Surface Modifications
11.3.2 Cost of Exosome Exterior Modifications
11.4 Exogenous Internal Loading of Exosomes
11.4.1 Technologies for Internal Loading
11.4.1.1 Electroporation
11.4.1.3 Extrusion
11.4.1.4 Saponin-Assisted Loading
11.4.1.5 Freeze-Thaw Cycling
11.4.1.6 Direct Incubation
11.5 Drugs Loaded Exogenously into Exosomes
11.5.1 Companies Developing Drug-Loaded Exosomes
11.5.2 Drug-Loaded Exosomes in the Ongoing Clinical Trials
11.5.3 Preclinical Studies using Dreug-Loaded Exosomes

12.1 Exosome-Based Therapeutic Candidates in Phase III
12.1.1 Deramiocel (CAP-1002)
12.1.1.1 FDA Approval Status
12.1.2 ExoFlo (Direct Biologics)
12.1.2.1 Core Applications and Pipeline
12.1.2.2 Clinical Data and Efficacy
12.1.3 PEP Biologic (INTENT Biologics)
12.2 Core Therapeutic Exosome Platforms & Technologies
12.2.1 Cost of Developing a Therapeutic Exosome Platform
12.2.1.1 Typical Exosome Licensing Deal Structure
12.2.2 Examples of Therapeutic Exosome Platforms
12.2.2.1 ExoEdit® Platform
12.2.2.2 DeliverEX™ Platform
12.2.2.3 StealthX™ Platform
12.2.2.4 ExoFlo™ Platform
12.2.2.5 AGLE-102 Platform
12.2.2.6 AB126 Platform
12.2.2.7 BG-Platform
12.2.2.8 Microalgae Extracellular Vesicles (MEVs)
12.2.2.9 Hybridosome® Platform
12.2.2.10 EVENGI Platform
12.2.2.11 XoGlo® Platform
12.2.2.12 Triple-A platform
12.2.2.13 REGENT® platform
12.2.2.14 EXPLOR® Platform
12.2.2.15 Exo-Target® Platform
12.2.2.16 Kuragenx Platform
12.2.2.17 EVerGel™ Platform
12.2.2.18 Eviv Platform
12.2.2.19 EVOGEX platform
12.3 Cost of Developing an Exosome-Based Therapeutic
12.3.1 Better Clinical Utility of Exosomes

13.1 Advantages of Exosome-Based Diagnostic Tests
13.2 Major Indications Focused by Developers of Exosome Diagnostics
13.2.1 Oncology
13.2.2 Neurology & Neurodegenerative Diseases
13.2.3 Other Major Indications
13.3 Major Milestones Achieved in Exosome-Based Diagnostic Sector
13.3.1 High-Sensitivity Technologies
13.3.2 Commercialization of Exosome-Based Tests
13.3.3 Cost of Developing an Exosome-Based Diagnostic
13.3.4 R&D and Biomarker Discovery
13.3.5 Analytical Validation & Assay Optimization
13.3.6 Clinical Trials & Validation
13.3.7 Regulatory & Commercialization
13.4 Diagnostic Exosome-Based Late-Stage Clinical Pipeline
13.4.1 Key Pipeline Tests & Companies
13.5 Exosome-Based Diagnostics in Development by Indication
13.5.1 Companies Developing Exosome-Based Diagnostics for Lung Cancer
13.5.2 Companies Developing Exosome Diagnostics for Pancreatic Cancer
13.5.3 Companies Developing Exosome-Based Diagnostics for Ovarian Cancer
13.5.4 Companies Developing Exosome Diagnostics for Cardiovascular Diseases
13.5.5 Companies Developing Exosome Diagnostics for Urology Indications
13.5.6 Companies Developing Exosome Diagnostics for Organ Transplantation
13.5.7 Companies Developing Exosome-Based Diagnostics for Pregnancy
13.6 Exosome Diagnostics Approaching Market Readiness
13.7 Future of Exosome Diagnostic Industry

14.1 Exosomes in Skin Rejuvenation & Anti-Aging
14.1.1 Exosome Skin Rejuvenation & Anti-Aging Products in the Market
14.1.1.1 Professional & Clinical-Grade Aesthetic Exosome Products
14.1.1.2 At-Home "Exosome-Inspired" Skincare Products
14.2 Exosome-Based Hair Regeneration
14.3 Exosome-Based Scar Reduction
14.4 Exosome-Based Pigmentation Regulation
14.5 Exosome-Based Post-Procedure Recovery Products
14.6 Percent Share Utilization of Medical Aesthetic Products by Type
14.7 Primary Sources of Exosomes for Medical Aesthetic Companies
14.8 Countries with the largest Utilization of Medical Aesthetics
14.9 More Examples of Exosome-Based Medical Aesthetics
14.9.1 Exosome-Based Serums
14.9.2 Exosome-Based Masks
14.9.3 Exosome-Based Creams
14.9.4 Exosome-Based Lotions
14.9.5 Exosome-Based Haircare Aesthetics
14.9.6 Human-Derived Exosome-Based Aesthetics
14.9.7 Plant-Derived Exosome-Based Aesthetics
14.9.8 Animal-Derived Exosome-Based Aesthetics

15.1 Market for Exosome Research Products
15.2 Exosome Development & Manufacturing Market
15.2.1 Global Market for Exosome Development & Manufacturing Services
15.3 Global Market for Exosome Diagnostics
15.4 Market for Exosome-Based Medical Aesthetics
15.5 Global Market for Exosome-Based Aesthetics by Geography, 2006-2034
15.5.1 Percent Share of Exosome-Based Skincare Products by Type
15.5.2 Percent Share of Exosome-Based Skincare Products by Cell Source
15.6 Global Market for Exosome-Based Therapeutics
15.7 Global Market for “Ready-To-Use” Exosomes
15.8 The Overall Global Market for Exosome-Based Products

16.1 Abcam plc
16.1.1 Core Exosome Product Portfolio
16.1.1.1 Immunophenotyping & Marker Detection
16.1.1.2 Specific Isolation Kits
16.1.1.3 Quantification & Assay Platforms
16.2 AcouSort AB
16.2.1 Acoustofluidic Separation
16.2.2 The AcouSome Project
16.2.3 AcouTrap Platform
16.3 Aegle Therapeutics
16.3.2 Clinical Milestones
16.4 Aethlon Medical, Inc.
16.4.1 The Hemopurifier
16.4.2 Oncology Clinical Trials
16.5 AGS Therapeutics
16.5.1 Clinical Programs
16.6 Akrivis Health Care Pvt., Ltd.
16.6.1 Core Business & Products
16.6.1.1 SynExo
16.6.1.2 TympanoSeal™
16.7 AnswerBio
16.7.1 Technology
16.8 AnteAGE
16.8.1 Exosome-Based Products
16.8.1.1 AnteAGE MDX® Exosome Solution
16.8.1.2 AnteAGE Biosomes™
16.9 Aposcience AG
16.9.1 APOSEC™
16.10 Aruna Bio, Inc.
16.10.1 Lead Therapeutic Candidate (AB-126)
16.11 Ascension Medical Biotechnology Co., Ltd. (AM BioTech)
16.11.1 Bio-Pulsed Platform
16.11.2 ExoGiov
16.11.3 Key Applications & Products
16.12 BioCat GmbH
16.12.1 Key Focus Areas & Solutions
16.13 BioFluidica
16.13.1 LiquidScan platform
16.13.2 Core Technology & Workflow
16.13.3 Key Clinical Applications
16.13.4 Advantages
16.14 Biorbyt, Ltd.
16.15 Bioscience Institute
16.15.1 Core Areas of Operation
16.15.2 Key Facilities
16.15.3 Exosome Services
16.16 Biosynth International, Inc.
16.16.1 Core Exosome Offerings
16.17 Bio-Techne Corporation
16.17.1 Key facets of Bio-Techne's exosome portfolio
16.18 BioXtek
16.18.1 Manufacturing & Facilities
16.18.2 Product Portfolio
16.18.3 Strategic Partnerships
16.19 BreStem Therapeutics, Inc.
16.19.1 Core Technologies and Pipeline
16.20 Capricor Therapeutics
16.20.1 StealthX™ Exosome Platform
16.20.2 Capricor’s Exosome-Based Clinical Programs
16.21 Carmine Therapeutics
16.21.1 REGENT® Platform
16.21.2 Industry Context and Therapeutic Focus
16.21.3 Pipeline and Commercial Milestones
16.22 Cellarcus Biosciences Inc.
16.22.1 Key Highlights
16.23 Cells for Cells
16.23.1 Cellistem®OA
16.24 Ciloa SAS
16.24.1 Core Technology Platform
16.24.2 Therapeutic Pipeline & Applications
16.25 ConveyXO
16.25.1 Exo-Harvest Technology
16.25.2 XomeXBio (RNA loading) Technology
16.25.3 Clinical Applications
16.25.3.1 Clinical Programs
16.26 Coya Therapeutics, Inc.
16.26.1 Exosome Platform Focus
16.26.2 Nanoengineering and Exosome-Polymer Hybrids (EPHs)
16.27 Craif, Inc.
16.27.1 Core Technology & Platform
16.27.2 Key Products and Applications
16.27.3 Global Expansion & Clinical Trials
16.28 Creative Bioarray
16.28.1 Key Exosome Services
16.28.2 Exosome Products Offered
16.28.3 Primary Context & Use Cases
16.29 Creative Biolabs
16.29.1 Core Exosome Services
16.29.2 Therapeutic & Clinical Applications
16.30 Creative Biostructure
16.30.1 Key Service & Product Areas
16.30.2 Primary Applications
16.31 Creative Medical Technology Holdings
16.31.1 Exosome-Focused Platforms and IP
16.32 Creative Proteomics
16.32.1 Key Exosome Services
16.33 CUSABIO Technology LLC
16.33.1 Exosome-Specific Products & Services
16.34 Danaher Corporation
16.34.1 Key Operating Companies & Their Contributions
16.34.2 Applications in Research and Medicine
16.35 Diadem Biotherapeutics
16.35.1 DECOSTAR™
16.36 Direct Biologics
16.36.1 Clinical Programs
16.37 DynaCord Stem Cell Research
16.37.1 Core Exosome Focus & Services
16.37.2 Dynacord's Core R&D Focus
16.38 Elevai Skincare
16.38.1 Core Technology & Science
16.38.2 Key Product Lines
16.38.2.1 ELEVAI enfinity™
16.38.2.2 ELEVAI empower™
16.39 Entelexo Biotherapeutics
16.39.1 Core Technology & Pipeline
16.40 EriVan Bio
16.40.1 Core Offerings & Capabilities
16.41 Esphera SynBio Inc.
16.41.1 Core Technology & Pipeline
16.42 Ever Supreme Bio Technology Co., Ltd.
16.42.1 EXO 001 Platform
16.42.2 The aDAT-EV Platform
16.43 EVerZom
16.43.1 EVerGel
16.43.2 EViv
16.44 Evolutionary Biologics (EVOBIO)
16.44.1 Key Products & Applications
16.44.1.1 EVO Hybrid
16.44.1.2 EVO ELIXIR
16.44.1.3 EVO GRO
16.44.1.4 EXO PERIO
16.45 Evora Biosciences
16.45.1 EVO-003
16.45.2 EVOGEX
16.46 Evox Therapeutics Limited
16.46.1 ExoEdit Platform
16.46.2 Core Pipeline Programs
16.47 EV Therapeutics
16.47.1 mTEV Immunotherapy Platform
16.48 EXO Biologics SA
16.48.1 ExoPulse Technology
16.49 ExoCan Healthcare
16.49.1 ExoEnrich™
16.50 Exocel Bio
16.50.1 The Exovex™ Serum Line
16.51 Exogenus Therapeutics SA
16.51.1 EXO-101
16.52 Exokeryx, Inc.
16.52.1 Core Technology & Products
16.52.2 Demeter EVPrep
16.52.3 ExoScan
16.53 ExoLab Italia
16.53.1 Key Corporate Highlights
16.54 EXORPHIA, Inc.
16.54.1 Core Platforms & Pipeline
16.55 Exosome Plus
16.55.1 ExoThera Platform
16.56 Exosome Sciences, Inc.
16.56.1 TauSome™ Biomarker
16.57 Exosomics S.p.A.
16.57.1 Technologies
16.57.1.1 SeleCTEV™ DNA Enrichment kit
16.57.1.2 SoRTEV platform
16.58 ExoStemTech Co., Ltd
16.58.1 CARTISOME®
16.58.2 EST-T-EXO
16.58.3 HEPATOSOME®
16.58.4 HYPOXISOME®
16.59 ExoTop Theragnostics, Inc.
16.59.1 Key Operations & Services
16.60 ExoVectory B.V.
16.61 ExoXpert
16.61.1 ExoPulse Platform
16.61.2 Services Available
16.62 ExSURE
16.62.1 ExoDS Platform
16.62.2 Commercial Products
16.63 FYR Bio
16.63.1 EV-Omics (EVO) Platform Technology
16.63.1.1 Clinical & BioPharma Applications
16.63.2 SPARCs™ Technology
16.63.2.1 Core Applications and Impact
16.64 GBI Biomanufacturing
16.64.1 GBI's Role in Exosome Development
16.65 HansaBioMed Life Sciences, Ltd.
16.65.1 Core Offerings & Technology
16.66 Hexun Life Science Co., Ltd.
16.66.1 Core Business and Pipeline
16.67 Hilltop Bio
16.67.1 Regenaflex-RT
16.67.1.1 Primary Indications and Uses
16.67.2 Strydaflex and Strydaflex-K9
16.67.3 Strydaflex (Equine)
16.67.4 Strydaflex-K9 (Canine)
16.67.5 Regenaflex-M
16.68 Human Continuum Inc.
16.68.1 Core Focus Areas
16.69 ILIAS Biologics
16.69.1 EXPLOR® Technology
16.69.2 Exo-Target® Technology
16.69.3 Lead Product Candidate
16.69.3.1 Clinical Status
16.70 INEXOPLAT Inc.
16.70.1 Core Focus & Pipeline
16.71 InnoCan Pharma
16.71.1 CLX Platform
16.72 Innovex Therapeutics, SL
16.72.1 Key Research & Pipeline
16.73 INOVIQ
16.73.1 NETs technology
16.73.1.1 Clinical Applications
16.73.2 SubB2M Platform
16.73.2.1 Applications and Clinical Focus
16.73.3 Clinical Programs
16.74 INTENT Biologics
16.74.1 Products
16.75 Irazu Oncology, LLC
16.75.1 Outer Membrane Vesicle Platform
16.75.2 Lead Therapeutic Candidates
16.76 Izon Science Limited
16.76.1 Solutions Provided by Izon
16.76.1.1 Nanoparticle Analysis Solution
16.76.1.2 Isolation & Separation Solutions
16.76.2 Main Product Lines
16.76.2.1 Nanoparticle Analysis Instruments
16.76.2.2 Isolation & Separation Systems
16.77 JY BioMed
16.77.1 Exosome Platforms & R&D
16.77.2 Pipeline & Technology
16.78 Kimera Labs
16.78.1 Vive
16.78.2 Luxir & Luxir +
16.79 LongEVity Bioscience
16.79.1 Core Focus & Product Brands
16.79.1.1 PHYTOXOME
16.79.1.2 JUVEV EXOGLOW
16.79.2 Nutritional Supplements
16.80 Lonza Group AG
16.80.1 Core Capabilities & Technologies
16.81 MDxHealth
16.81.1 SelectMDx
16.81.1.1 Coverage and Insurance
16.81.2 ConfirmMDx
16.82 Mercury Bio, Inc.
16.82.1 Technology
16.83 Mercy BioAnalytics, Inc.
16.83.1 The Mercy Halo™ Platform
16.83.1.1 Clinical Focus and Progress
16.83.2 The Evident Test
16.83.2.1 Clinical Efficacy & Current Status
16.84 Micregen Ltd.
16.84.1 Secretomix®
16.84.2 Core Pipeline & Indications
16.85 Microgentas, Inc.
16.85.1 Business Divisions
16.85.1.1 EV Isolation Services
16.85.1.2 EV Characterization Services
16.85.2 Product Line Up
16.85.2.1 ExoPAS™
16.85.2.2 ExoCAS-2™
16.85.2.3 ExoFilter™
16.85.2.4 ExoTFF™
16.85.2.5 miRQuick™
16.85.2.6 ExoSCAN™
16.85.2.7 gTx
16.85.2.8 JUVEV™
16.86 Miltenyi Biotec
16.86.1 Core Exosome Technologies
16.86.1.1 Target Applications
16.87 MiRNA Scientific
16.87.1 Core Platform & Products
16.88 Mursula Bio
16.88.1 EvoLiver®
16.89 Nano24 (formerly OBCTCD24)
16.89.1 Core Technology
16.89.2 Clinical Focus & Pipeline
16.90 NanoSomix, Inc.
16.90.1 Technology
16.91 Neucore Bio
16.91.1 Technology & Research
16.92 NeuroDex
16.92.1 Core Technology & Pipeline
16.92.2 Proprietary ExoSort Platform
16.92.2.1 Key Advantages & Capabilities
16.93 NeuroSense Therapeutics
16.93.1 Exosome-Based Research & Partnerships
16.94 Norgen Biotek Corporation
16.94.1 Core Exosome Technologies
16.94.2 Product Portfolio
16.95 Novaxomx GmbH
16.96 Novus Biologicals, LLC
16.96.1 Key Exosome Research Tools
16.96.2 Target Research Areas
16.97 Nucelion Therapeutics Private Limited
16.97.1 Nucelion in the Exosome Context
16.98 NX Prenatal, Inc.
16.98.1 NeXosome Platform
16.98.2 Core Clinical Applications
16.99 Oasis Diagnostics® Corporation
16.99.1 Pure•SAL™
16.99.2 RNAPro•SAL™
16.100 OmniSpirant Therapeutics
16.100.1 OmniSomes Platform
16.100.1.1 Key Features and Capabilities
16.100.2 Pipeline Indications
16.101 OncoXome, Inc
16.102 Paracrine Therapeutics Pte, Ltd.
16.103 PranaX Corporation
16.103.1 Core Technology
16.104 Prediction Biosciences
16.105 QIAGEN N.V.
16.105.1 Core Exosome Capabilities
16.106 Regen Suppliers
16.106.1 Product Portfolio & Services
16.107 Regenerelle LLC
16.108 ReNeuron
16.108.1 CustomEX™ Technology
16.109 Resiliélle Cosmetics LLC
16.109.1 Product Offerings
16.110 Rhythm Biotherapeutics
16.110.1 RBex
16.111 RION
16.111.1 Purified Exosome Product (PEP™)
16.112 Rosetta Exosome Co., Ltd.
16.112.1 ExoLutE®
16.113 RoosterBio, Inc.
16.113.1 Core Focus
16.113.2 Platforms & Partnerships
16.113.3 Services
16.114 ShiftBIO
16.114.1 Programmable NNP Platform
16.115 Shine-On Biomedical Co., Ltd.
16.115.1 Core Technology & Pipeline
16.115.1.1 Targeted Exosome Platforms (SOB Series)
16.115.1.2 Trispecific Antibody Platforms (SOA Series)
16.116 Somestech Biotechnology Co., Ltd.
16.116.1 Core Platforms & Technology
16.117 Souvie Biodelivery, LLC
16.117.1 Technology & Focus
16.118 Stemcell Medicine Ltd.
16.118.1 Exosome Focus & Therapeutic Applications
16.119 STRM.BIO
16.119.1 Core Technology & Platform
16.119.2 Therapeutic Pipeline & Focus
16.120 System Biosciences (SBI)
16.120.1 Core Exosome Focus Area
16.120.2 Value to the Scientific Community
16.121 Takara Bio, Inc.
16.121.1 Exosome-Specific Product Portfolio
16.121.2 Isolation & Purification Kits
16.121.3 Specialized Stem Cell Media
16.121.4 Downstream Multiomics Integration
16.122 Terasom Ltd.
16.122.1 Core Focus & Technology
16.123 Thermo Fisher Scientific
16.123.1 Core Exosome Workflow Solutions
16.123.2 Applications & Strategic Focus
16.124 The Tiny Cargo Company
16.124.1 Key Advantages
16.125 TransGen Biotech Co., Ltd.
16.125.1 TransExo® PS Exosome Isolation Kit
16.125.2 TransExo® Cell Media Exosome Kit
16.126 Tymora Analytical Operations
15.126.1 EVtrap
16.126.2 pIMAGO & PolyMAC
16.127 Unchained Labs
16.127.1 The Leprechaun Platform
16.128 Unicyte AG
16.128.1 Human Liver Stem Cells (HLSCs)
16.128.1.1 Key Characteristics and Therapeutic Applications
16.128.2 Functional Pancreatic Islets
16.128.2.1 Core Technology
16.129 Urvogelbio Pvt. Ltd.
16.129.1 Research & Technology Focus
16.130 Versatope Therapeutics, Inc.
16.130.1 Versatope's Exosome
16.130.2 Current Pipeline & Developments
16.131 VesiCURE Therapeutics
16.131.1 modEXO Platform
16.131.2 dilEVry Platform
16.131.2.1 Key Capabilities of the dilEVry Platform
16.132 VivaZome Therapeutics Pty Ltd
16.132.1 Core Technologies & Therapeutics
16.133 Xosomix
16.133.1 Core Technology & Focus
16.134 XOStem, Inc.
16.134.1 Core Focus & Technology
16.135 ZEO ScientifiX, Inc.
16.135.1 Key Products & Pipeline

FIGURE 2.1: Biogenesis of Exosomes
FIGURE 2.2: Uptake of Exosomes by Target Cell
FIGURE 2.3: Structure of an Exosome
FIGURE 3.1: The Growth in Volume of Published Papers on Exosomes, 2010-2025
FIGURE 3.2: Number of PubMed.gov Published on Diagnostic Exosomes, 2010-2025
FIGURE 3.3: Number Papers on Exosome’s Application in Targeted Drug Delivery
FIGURE 3.4: Number of Published Papers on Therapeutic Application of Exosomes
FIGURE 3.5: Higher Output of Published Papers on Exosome Therapeutics
FIGURE 3.6: Percent Share of Exosome Cargo Loading Technologies
FIGURE 3.7: Percent Share of Exosome Purification Technologies in Research
FIGURE 3.8: Distribution of Exosome Publications by Disease Type
FIGURE 3.9: Exosome-Based PubMed Publications by Cancer Type
FIGURE 3.10: The Geographical Split of Exosome Publications
FIGURE 4.1: The Steady Growth in Number of Patent Filings, 2000-2026
FIGURE 4.2: Percent Share of Exosome Patent Filings by Primary Domains of Innovation
FIGURE 5.1: Percent Share of Clinical Trials by Geography
FIGURE 5.2: Exosome-Based Clinical Trials by Application
FIGURE 5.3: Percent Share of Diseases Addressed by Exosome-Based Clinical Trials
FIGURE 13.1: Major Indications Focused for Diagnosis
FIGURE 13.2: Share of Disease Indications Focused on by Exosome Diagnostics
FIGURE 14.1: Percent Share Utilization of Medical Aesthetic Products by Type
FIGURE 14.2: Percent Share of Exosome-Based Aesthetic Utilization by Geography
FIGURE 15.1: Estimated Market for Exosome Research Products, 2026-2034
FIGURE 15.2: Market for Exosome Development & Manufacturing Services, 2026-2035
FIGURE 15.3: Global Exosome Diagnostics Market by Geography, 2026-2034
FIGURE 15.4: Global Market for Exosome-Based Aesthetics by Product Type, 2026-2034
FIGURE 15.5: Global Market for Exosome-Based Aesthetics by Geography, 2026-2034
FIGURE 15.6: Percent Share of Exosome-Based Skincare Products by Type
FIGURE 15.7: Percent Share of Exosome-Based Skincare Products by Cell Source
FIGURE 15.8: Estimated Market for Exosome-Based Therapeutics, 2026-2034
FIGURE 15.9: Global Market for Ready-To-Use Exosomes, 2026-2034
FIGURE 15.10: Global Market for all its Market Segments by Geography, 2026-2034

TABLE 2.1: Molecular Contents of Exosomes
TABLE 2.2: Companies Shifting from Cell Therapy to Exosome Therapy
TABLE 2.3: Key Scientific Milestones in the Medical Evolution of Exosomes
TABLE 2.4: Key Scientific Milestones in Exosome Therapeutics
TABLE 2.5: Key Scientific Milestones in Exosome Diagnostics
TABLE 2.6: Key Scientific Milestones in Exosome-Based Aesthetics
TABLE 2.7: Current Trends in Exosome Research
TABLE 2.8: Current Trends in Exosome Patent Filings
TABLE 2.9: Current Trends in Exosome-Based Clinical Trials
TABLE 3.1: Cost of Research & Publishing One Exosome Research Paper
TABLE 3.2: Leading Exosome Research Institutions
TABLE 3.3: Collaborations between Research Institutions and Commercial Entities
TABLE 4.1: Exosome Patent Filing Jurisdictions
TABLE 4.2: Exosome Patent Applicants as of June 2026
TABLE 4.3: Exosome Patent Inventors as of June 2026
TABLE 4.4: Owners of Filed Exosome Patents as of June 2026
TABLE 4.5: Legal Statuses of Filed Patents
TABLE 4.6: Recently Granted Notable Exosome Patents
TABLE 4.7: Examples of Exosome Patents Licensed
TABLE 4.8: Number of Patents Held by Select Exosome Companies
TABLE 5.1: Exosome-Based Clinical Trials by Country
TABLE 5.2: Exosome Study Phases
TABLE 5.3: Funding for Clinical Trials
TABLE 5.4: Examples of Industry Sponsored Clinical Trials
TABLE 5.5: Select Clinical Trials Evaluating Exosomes as Cell-Free Therapeutics
TABLE 5.6: Select Clinical Trials Evaluating Exosomes as Disease Diagnostics
TABLE 5.7: Select Clinical Trials Evaluating Exosomes as Drug Delivery Vehicles
TABLE 6.1: Venture Capital Funding Mobilized by Exosome Companies, 2023- June 2026
TABLE 6.2: Partnership Deals in Exosome Sector, 2023-June 2026
TABLE 6.3: Acquisition Deals in Exosome Space, 2023-June 2026
TABLE 6.4: Licensing Deals in Exosome Space, 2023-June 2026
TABLE 7.1: Key Isolation and Purification Technologies
TABLE 7.2: Top Ten Widely Utilized Exosome Isolation & Purification Kits
TABLE 8.1: Key Technologies & Methods in Upstream Processing of Exosomes
TABLE 8.2: Market-Leading Stirred-Tank Bioreactors
TABLE 9.1: Key Technologies for Exosome Clarification
TABLE 9.2: Key Technologies Involved in Concentration & Purification
TABLE 11.1: Companies with the Expertise for Exosome Engineering
TABLE 11.1: Companies Developing Exosomes by Endogenous Loading
TABLE 11.2: Companies Developing Exosomes by Exogenous Loading
TABLE 11.3: Molecules attached to Exosomes for Surface Modifications
TABLE 11.4: Technologies for Exogenous Internal Loading of Exosomes
TABLE 11.5: Therapeutics Loaded into Exosomes
TABLE 11.6: Companies Developing Drug-Loaded Exosomes
TABLE 11.7: Drug-Loaded Exosomes in the Ongoing Clinical Trials
TABLE 11.8: Preclinical Studies using Drug-Loaded Exosomes
TABLE 12.1: Prominent Commercial Firms Developing Exosome Therapeutics
TABLE 12.2: Development Timeline for Deramiocel
TABLE 12.3: Core Therapeutic Exosome Platforms & Technologies
TABLE 13.1: Cost of Developing an Exosome-Based Diagnostic Test
TABLE 13.2: Companies Developing Exosome-Based Diagnostics for Lung Cancer
TABLE 13.3: Companies Developing Exosome-Based Diagnostics for Pancreatic Cancer
TABLE 13.4: Companies Developing Exosome-Based Diagnostics for Ovarian Cancer
TABLE 13.5: Companies Developing Exosome Diagnostics for Cardiovascular Diseases
TABLE13.6: Companies Developing Exosome Diagnostics for Urology Indications
TABLE 13.7: Companies Developing Exosome Diagnostics for Organ Transplantation
TABLE 13.8: Companies Developing Exosome-Based Diagnostics for Pregnancy
TABLE 13.9: Exosome Diagnostics Approaching Market Readiness
TABLE 14.1: Specific Applications of Exosomes in Medical Aesthetics
TABLE 14.2: Regenerative Processes Initiated by Exosome-based Anti-Aging Products
TABLE 14.3: Professional & Clinical-Grade Aesthetic Exosome Products
TABLE 14.4: Popular At-Home "Exosome-Inspired" Skincare Products
TABLE 14.5: Exosome-Based Hair Regeneration Products
TABLE 14.6: Popular Exosome-Based Scar Reduction Products
TABLE 14.7: Exosome-Based Pigmentation Regulation Products
TABLE 14.8: Exosome-Based Post-Procedure Recovery Products
TABLE 14.9: Sources of Exosomes for Medical Aesthetic Companies
TABLE 15.1: Market Leaders in Exosome Research Products
TABLE 15.2: Estimated Market for Exosome Research Products, 2026-2034
TABLE 15.3: Leading Market Players in Exosome Development
TABLE 15.4: Leading Market Players in Exosome Manufacturing Services
TABLE 15.5: Market for Exosome Development & Manufacturing Services, 2026-2035
TABLE 15.6: Global Exosome Diagnostics Market, 2026-2034
TABLE 15.7: Global Market for Exosome-Based Aesthetics by Product Type, 2026-2034
TABLE 15.8: Global Market for Exosome-Based Aesthetics by Geography, 2026-2034
TABLE 15.9: Global Market for Ready-To-Use Exosomes, 2026-2034
TABLE 15.10 The Overall Global Market for Exosome-Based Products
TABLE 16.1: Leading Companies in Exosome-Based Therapeutics Sector
TABLE 16.2: Leading Companies in Exosome-Based Diagnostics Sector
TABLE 16.3: Leading Companies in Exosome-Based Research Tools
TABLE 16.4: CROs Offering Custom Services
TABLE 16.5: Leading Companies in Exosome-Based Aesthetics
TABLE 16.6: Aegle Therapeutics’ Clinical Pipeline
TABLE 16.7: AGS Therapeutics’ Clinical Focus
TABLE 16.8: Aruna Bio’s Clinical Programs
TABLE 16.9: Capricor Therapeutics’ Clinical Programs
TABLE 16.10: Ciloa’s Clinical Programs
TABLE 16.11: ConveyXO’s Therapeutic Pipeline
TABLE 16.12: Direct Biologics’ Clinical Pipeline
TABLE 16.13: EVerZom's Clinical Pipeline
TABLE 16.14: Evox Therapeutics’ Clinical Pipeline
TABLE 16.15: EV Therapeutics’ Clinical Programs
TABLE 16.16: EXO Biologics’ Clinical Programs
TABLE 16.17: Exogenus Therapeutics’ Clinical Programs
TABLE 16.18: INOVIQ’s Clinical Programs